FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Wash

washington, D.C. 20049	OMB APPROVAL			
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP	OMB Number:	3235-		

OMB Number:	3235-0287
Estimated average burd	len
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* SATO VICKI L				V	2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX]										eck all applic Directo	lationship of Reportir ck all applicable) Director Officer (give title below)		on(s) to Issi 10% Ov Other (s below)	vner	
(Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED						Date o /26/2		est Trai	nsact	ion (Mo	onth/C	ay/Year)		·	President					
130 WAVERLY STREET (Street) CAMBRIDGE MA 02139					4. 1	f Ame	ndme	nt, Date	of O	riginal f	Filed	(Month/Da	Line	Individual or Joint/Group Filing (Check Applicable ine) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(S	tate)	(Zip)																	
		Tab	le I - Nor	n-Deriv	vativ	e Se	curit	ies A	cqu	ired,	Disp	osed o	f, o	r Ben	eficial	y Owned				
Date		Date	Transaction ate Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)			3. Transaction Code (Instr.)		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 5)				Benefici Owned F	es ially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
							ĺ	Code	v	Amount		(A) or (D)	Price		Transaction(s) (Instr. 3 and 4)			(Instr. 4)		
Common Stock			05/2	05/26/2004 05/26/2004					M		7,000		A	\$6	195	195,108 188,108		D		
Common Stock		05/2						S ⁽¹⁾	7,000) D	\$8.64	188	D						
Common	Common Stock													7,	125		I ·	401(k)		
		-	Γable II -									sed of, onvertil				Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution I if any (Month/Day	Date,	ate, Transacti Code (Ins				6. Date Exercisal Expiration Date (Month/Day/Year)			Amount of			8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	Owne Form: Direct or Ind (I) (Ins	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exe	e rcisable		xpiration ate	Title		Amount or Number of Shares					
Stock	\$6	05/26/2004			M			7,000	03/0	08/1995 ⁽	(2) 1	2/07/2004		nmon	7,000	\$0	1,123,0	09	D	

Explanation of Responses:

- $1.\ Transaction\ made\ pursuant\ to\ Dr.\ Sato's\ company\ approved\ trading\ plan\ established\ under\ Rule\ 10b5-1.$
- 2. Right to buy under 1994 Stock and Option Plan, vesting quarterly over 5 years from 12/8/1994.

Remarks:

Kenneth S. Boger, Attorney-In-05/27/2004

Fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.